secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001140361-25-022267
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis CDO Richard Geary retiring Jan 2026; Holly Kordasiewicz to succeed
------------------------------------------------------------------------

- Richard Geary, EVP & chief development officer, will retire effective January 2026 after 30 years at Ionis.
- Holly Kordasiewicz, currently SVP neurology, to become EVP & chief development officer in January 2026.
- Geary led 50+ IND submissions and 6 FDA/EU approvals including TRYNGOLZA; will stay as strategic consultant in 2026.
- Kordasiewicz has 20 years R&D experience and played key role in QALSODY and IONIS-MAPT Rx Alzheimer's program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/0001140361-25-022267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/ef20050532_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-022267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer